CLINICAL_TRIALS
trial_result
· 2026-02-10
Clinical Trial Update: GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) [Phase 2]
Summary
A Phase 2 trial evaluating subcutaneous GV1001 for progressive supranuclear palsy has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GemVax & Kael | Conditions: Progressive Supranuclear Palsy | Phase 2 | Status: COMPLETED | Results posted: 2026-02-10